Parthenolide sensitizes hepatocellular carcinoma cells to trail by inducing the expression of death receptors through inhibition of STAT3 activation

Journal of Cellular Physiology

Volumn 226, Issue 6, 2011, Pages 1632-1641

  Carlisi, Daniela ^a   D'Anneo, Antonella ^a   Angileri, Liliana ^a   Lauricella, Marianna ^a   Emanuele, Sonia ^a   Santulli, Andrea ^a   Vento, Renza ^a   Tesoriere, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; JANUS KINASE; MESSENGER RNA; PARTHENOLIDE; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASES; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; JANUS KINASES; LIVER NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, DEATH DOMAIN; SESQUITERPENES; STAT3 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53;

TANACETUM PARTHENIUM;

EID: 79952711704     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22494     Document Type: Article

References (55)

1. Baeuerle PA, Baltimore D. 1996. NF-kappa B: Ten years after. Cell 87: 13-20.
2. Beg AA, Baltimore D. 1996. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784.
3. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J. 2000. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2: 241-243.
4. Bork PM, Schmitz ML, Kuhnt M, Escher Heinrich M. 1997. Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 402: 85-90.
5. Bowman T, Garcia R, Turkson J, Jove R. 2000. STATs in oncogenesis. Oncogene 19: 2474-2488.
6. Carlisi D, Lauricella M, D'Anneo A, Emanuele S, Angileri L, Di Fazio P, Santulli A, Vento R, Tesoriere G. 2009. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 45: 2425-2438.
7. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115.
8. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL. 2009. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 284: 11121-11133.
9. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
10. Dzieran J, Beck JF, Sonnemann J. 2008. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. Cancer Sci 99: 1685-1692.
11. Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R, Tesoriere G. 2007. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12: 1327-1338.
12. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 14363-14367.
13. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H. 2004. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11: S86-S96.
14. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ. 2005. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 11: 6333-6341.
15. Giuliano M, Lauricella M, Calvaruso G, Carabillò M, Emanuele S, Vento R, Tesoriere G. 1999. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 59: 5586-5595.
16. Gopal YN, Chanchorn E, Van Dyke MW. 2009. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther 8: 552-562.
17. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT. 2005. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105: 4163-4169.
18. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Dröge W, Schmitz ML. 1998. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 273: 1288-1297.
19. Ihle JN. 1996. STATs: Signal transducers and activators of transcription. Cell 84: 331-334.
20. Ivanov VN, Zhou H, Partridge MA, Hei TK. 2009. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res 69: 3510-3519.
21. Jong-Hyun K, Lan L, Seung-Ok L, Yong-Tae K, Kyung-Ran Y, Dae-Ghon K. 2005. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res 65: 6312-6320.
22. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL. 2009. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate 69: 827-837.
23. Kroemer G, Galluzzi L, Brenner C. 2007. Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99-163.
24. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. 2001. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 deathinducing signaling complex. J Biol Chem 276: 20633-20640.
25. Kruse JP, Gu W. 2009. Modes of p53 regulation. Cell 137: 609-622.
26. Kurdi M, Booz GW. 2007. Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: Parthenolide targets JAK1 activation by generating ROS. J Cell Physiol 212: 424-431.
27. Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, Motoyoshi Y, Taura N, Ichikawa T, Hamasaki K, Eguchi K. 2007. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol 47: 546-555.
28. Lesiak K, Koprowska K, Zalesna I, Nejc D, Düchler M, Czyz M. 2009. Parthenolide, a sesquiterpene lactone from the medical herb fever few, shows anticancer activity against human melanoma cells in vitro. Melanoma Res 20: 21-34.
29. Ling X, Arlinghaus RB. 2005. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 65: 2532-2536.
30. Liu X, Yue P, Khuri FR, Sun SY. 2004. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64: 5078-5083.
31. Li-Weber M, Palfi K, Giaisi M, Krammer PH. 2005. Dual role of the anti-inflammatory sesquiterpene lactone: Regulation of life and death by parthenolide. Cell Death Differ 12: 408-409.
32. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. 1997. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 272: 25417-25420.
33. Meek DW. 2009. Tumour suppression by p53: A role for the DNA damage response? Nat Rev Cancer 9: 714-723.
34. Miglietta A, Bozzo F, Gabriel L, Bocca C. 2004. Microtubule-interfering activity of parthenolide. Chem Biol Interact 149: 165-173.
35. Nakshatri H, Rice SE, Bhat-Nakshatri P. 2004. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23: 7330-7344.
36. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, Yu H. 1999. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59: 5059-5063.
37. Pajak B, Gajkowska B, Orzechowski A. 2008. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells: Folia Histochem Cytobiol 46: 129-135.
38. Pasquini L, Petrucci E, Riccioni R, Petronelli A, Testa U. 2006. Sensitivity and resistance of human cancer cells to TRAIL: Mechanisms and therapeutical perspectives. Cancer Ther 4: 47-72.
39. Pellerito O, Portanova P, De Blasio A, Santulli A, Vento R, Calvaruso G, Tesoriere G, Giuliano M. 2010. The synthetic cannabinoid WIN sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis by activating CHOP/DR5 axis. Mol Pharmacol 77: 854-863.
40. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, Teufel A, Wörns M, Fischer T, Strand S, Lohse AW, Galle PR. 2006. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15: 227-230.
41. Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW, Jr., Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ. 2006. Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate 66: 1498-1511.
42. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821.
43. Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, Kim SJ, Hong SS, Park JH. 2002. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 34: 114-122.
44. Sobota R, Szwed M, Kasza A, Bugno M, Kordula T. 2000. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem Biophys Res Commun 267: 329-333.
45. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H. 2000. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609.
46. Suvannasankha A, Crean CD, Shanmugam R, Farag SS, Abonour R, Boswell HS, Nakshatri H. 2008. Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res 14: 1814-1822.
47. Takimoto R, El-Deiry WS. 2000. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19: 1735-1743.
48. Thanos D, Maniatis T. 1995. NF-kappa B: A lesson in family values. Cell 80: 529-532.
49. Walczak H, Sprick MR. 2001. Biochemistry and function of the DISC. Trends Biochem Sci 26: 452-453.
50. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163.
51. Wen J, You K, Lee S, Song C, Kim D. 2002. Oxidative stress-mediated apoptosis. J Biol Chem 277: 38954-38964.
52. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
53. Wilks AF. 2008. The JAK kinases: Not just another kinase drug discovery target. Semin Cell Dev Biol 19: 319-328.
54. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T, Suzuki A. 2000. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32: 482-490.
55. Zhao L, Wientjes MG, Au JL. 2004. Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10: 7994-8004.